Recruiting

LOVEA Prospective Randomized Multicentre Trial for Lymphadenectomy in Early-stage Ovarian Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy

+ Comprehensive staging surgery with no Lymphadenectomy

Procedure
Who is being recruted

Urogenital Diseases+12

+ Genital Diseases

+ Adnexal Diseases

From 18 to 70 Years
+14 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Interventional
Study Start: January 2021
See protocol details

Summary

Principal SponsorSun Yat-sen University
Study ContactJihong Liu, Ph.D.More contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 31, 2021

Actual date on which the first participant was enrolled.

OBJECTIVES: Compare the efficacy and safety in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA -IIA epithelial ovarian cancer, undergo completion staging surgery including systematic pelvic and para-aortic lymphadenectomy versus comprehensive staging surgery without lymphadenectomy. OUTLINE: This is a randomized phase III multicenter study. Patients will receive comprehensive staging surgery without Lymphadenectomy or completion staging surgery including systematic pelvic and para-aortic lymphadenectomy, and the adjuvant chemotherapy will accord to National Comprehensive Cancer Network (NCCN) guidelines. Patients are followed up every 3 months within the first 2 years, and then every 6 months. PROJECTED ACCRUAL: A total of 656 patients will be recruited for this study within 5 years.

Official TitleA Prospective Randomized Multicentre Trial for Lymphadenectomy in Early-stage Ovarian Cancer
NCT04710797
Principal SponsorSun Yat-sen University
Study ContactJihong Liu, Ph.D.More contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

656 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 70 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesAdnexal DiseasesEndocrine System DiseasesEndocrine Gland NeoplasmsFemale Urogenital Diseases and Pregnancy ComplicationsGenital Diseases, FemaleGenital Neoplasms, FemaleGonadal DisordersNeoplasmsNeoplasms by SiteOvarian DiseasesOvarian NeoplasmsUrogenital NeoplasmsFemale Urogenital Diseases

Criteria

4 inclusion criteria required to participate
Women aged 18 years to 70 years.
Primary diagnosis of epithelial ovarian cancer FIGO stage IA-IIA ( recevive no prior treatment or receive incomplete initial surgery)，with indications of adjuvant chemotherapy：①High-grade serous carcinoma; ②Grade 3 endometrioid carcinoma; ③Clear cell carcinoma; ④Grade 2 endometrioid carcinoma with capsule ruptured or pelvic tissues extension ⑤Low-grade serous carcinoma、Grade 1 endometrioid carcinoma and Mucinous carcinoma of the ovary with pelvic tissues extension.
Patients who have given their signed and written informed consent.
Good performance status (ECOG 0/1).
10 exclusion criteria prevent from participating
Non epithelial ovarian malignancies and borderline tumors.
Suspicious lymph nodes at preoperative radiological evaluation.
Intraoperative clinically suspicious lymph nodes (bulky nodes).
Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Active Comparator
Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy

Group II

Experimental
Comprehensive staging surgery with no Lymphadenectomy

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center

Guangzhou, ChinaOpen Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center in Google Maps
Recruiting
One Study Center